| || || |
|VisiVite Premier Ocular Formula Number 2|
Nutritional Eye Vitamin Formula based on AREDS 2
The National Eye Institute has announced their newest and most advanced
Macular Degeneration Formula Study. And VisiVite is the first and only vitamin
manufacturer to offer this unique supplement for the prevention of disease
progression and improvement of vision.
In 2001, the National Eye Institute, part of the National Institutes of Health,
completed the Age Related Eye Disease Study (AREDS), which showed that ingesting
high levels of specific nutritional supplements decreased the risk of macular
degeneration (AMD) progression. This included 25,000 IU of beta-carotene, 500 mg
of Vitamin C, 400 IU of Vitamin E, 80 mg of Zinc and 2 mg of Cupric Oxide.
Unfortunately, while AREDS showed benefit against this retinal eye disease, if
did not demonstrate improvement in vision.
Since the publication of AREDS, more recent studies, including the Lutein
Antioxidant Supplement Trial, have demonstrated vision improvement. And much
exciting work involving both Lutein and Zeaxanthin, molecules known as
carotenoids, have shown not only vision improvement but also a healthier macular
appearance with improvement in pigmentation and color.
One important issue not addressed in AREDS is that there appears to be an
inflammatory component to Age-Related Macular Degeneration. Therefore, Omega-3
fatty acids derived from deep sea fish may be helpful in further counteracting
this eye disease and preventing blindness.
For these reasons, the National Eye Institute, in late 2006 announced the
recruitment of patients into a multi-year randomized Age Related Eye Disease 2
The Age Related Eye Disease Study 2 site states:
"The Age-Related Eye Disease Study 2 (AREDS2) is a multi-center, randomized
trial designed to assess the effects of oral supplementation of macular
xanthophylls (lutein and zeaxanthin) and/or long-chain omega-3 fatty acids (docosahexaenoic
acid) [DHA] and eicosapentaenoic acid [EPA] ) on the progression to advanced
age-related macular degeneration (AMD). An additional goal of the study is to
assess whether forms of the AREDS nutritional supplement with reduced zinc
and/or no beta-carotene works as well as the original supplement in reducing the
risk of progression to advanced AMD."
VisiVite Premier Ocular Formula Number 2 is based upon the prediction of the most successful
components and modifications of the Age Related Eye Disease Study 2.
It is recommended for the following patients with macular degeneration:
Progressive macular degeneration with vision loss in one or both eyes
Presence in the retina of large drusen, pigmentation or geographic atrophy
Safe for both smokers and non-smokers (does not contain beta-carotene)
| || |